Clinipace Worldwide Has Banner Year in 2013 - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Clinipace Worldwide Has Banner Year in 2013

Source: Company News Release

Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today the company has closed its strongest year to date, with a record number of new clinical development projects and regulatory and strategic development engagements; driving 114% growth in bookings compared to the previous year.

Much of the company’s success in 2013 can be attributed to new client acquisition within both its Clinical and Regulatory divisions, as well as strong demand for additional projects within its existing base of clients.
2013 by the numbers:

  • 63% year-over-year growth in consolidated revenues
  • 194% year-over-year growth in new bookings for full-service dCRO studies
  • Tripling of average contract value
  • 42% backlog growth
  • 2.0 book-to-bill ratio
  • 50 net new hires

“The continued growth in both new client acquisition and follow-on projects from existing clients demonstrates the level of trust and partnership we build with our clients,” said Jeff Williams, Clinipace Worldwide Founder and CEO. “We work hard to forge a real partnership with our clients and to provide efficiency and visibility into study and program management through our dCRO model.”

Clinipace also experienced solid growth in several therapeutic areas over the past year including oncology/hematology, infectious disease, gastroenterology, cardiovascular, nephrology, immunology, pediatrics, and women’s health. The company’s depth and breadth of expertise managing oncology clinical trials remains one of its strongest core competencies.

Clinipace hired 50 net new team members in 2013, and expects to expand by an additional 25% in 2014 to support continued growth. Areas of aggressive hiring included clinical monitoring, site management services, clinical project management, clinical data management, and financial operations.

Clinipace Worldwide was recognized this past year both regionally and nationally for its tremendous growth with several prestigious business awards. The company started off the year on a high note, ranking #36 in FORBES’ list of America’s 100 Most Promising Companies. In May, the Triangle Business Journal and accounting giant BDO honored Clinipace with one of its inaugural Life Sciences Awards. The company also was named to Inc. Magazine’s Inc. 500, upon generating a three-year growth rate of 918.55% from 2010 to 2012. This is the fourth consecutive year that Clinipace Worldwide has been recognized—an honor bestowed to few other companies in the nation. Clinipace was recognized for the fourth year in a row as one of the 50 fastest growing private companies in the Triangle at the Triangle Business Journal’s Fast 50 Awards. Clinipace also received the distinction of being chosen as an Inc. Magazine Hire Power Awards winner. Clinipace ranked 67th overall, placing it among the top 100 private business job creators in the country, 2nd in private business job creators within North Carolina, and 7th within the health industry.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Company News Release,
Click here